Healthcare / BiotechnologyTokyo
$1292.00
-136.00 (-9.52%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-3.8B · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$100.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-28.2%
↓Gross Margin
N/A
•Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.99x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-3.84B · FCF $-3.79B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Net Income | $-3.84B | $-3.84B | $-2.88B | $-2.64B | $-5.56B |
| EBITDA | $-4.25B | $-4.25B | $-2.99B | $-2.52B | $-4.65B |
| EPS | — | — | -40.48 | -40.48 | -95.99 |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.23 | 0.24 | 0.21 |
| Current Ratio | 29.01 | 29.01 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.79B | $-3.79B | $-3.61B | $-4.82B | $-7.44B |
| Returns | |||||
| ROE | -28.2% | -28.2% | -163.5% | -94.7% | -125.5% |
| Valuation | |||||
| P/B | 7.41 | 7.41 | 38.74 | 12.89 | 9.87 |
| Growth & Yield | |||||
| EPS Growth | — | — | 0.0% | 57.8% | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-62.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-40.48 → n/d
Residual
-62.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.